13.23
改良释药药物递送系统：速率程序控释 II
速率程序控释药物递送系统以可控方式释放药物，以维持治疗性浓度。主要有三种设计：储库型、基质型和混合型。
储库型系统由药物核及外包用于控制药物释放的膜组成。在非溶胀型储库系统中，使用乙基纤维素或聚甲基丙烯酸酯类等聚合物。这些聚合物在水性介质中不发生水化，通过膜的厚度、孔隙率或不溶性来控制药物释放。此类…
程序控速给药系统可分为三种设计：储库型、基质型或混合型。
储库系统将药物核心包裹在控释薄膜或膜内。
非膨胀型通过乙基纤维素和聚甲基丙烯酸酯类聚合物，利用膜厚度、不溶性、缓慢溶解或孔隙率来控制药物释放。膨胀型控制类型则常使用羟丙基甲基纤维素（HPMC）等聚合物，通过膜的水合作用延迟药物释放。
基质系统将药物包埋于缓释材料中。
亲水性骨架采用HPMC等可溶胀的聚合物，而疏水性骨架则使用蜡质或乙基纤维素。疏水性骨架可以是多孔的，将药物混合到聚合物中；也可以是非多孔的，将药物分散于熔融的聚合物中。
杂化系统将药物嵌入基质中，该基质包被有缓释材料，其外层进一步包被有控释聚合物。这种设计结合了储库型系统的稳定释药特性与基质型装置的耐久性，可有效控制药物释放。
View the full transcript and gain access to JoVE Core videos
Q1: What are the three main designs of rate-programmed drug delivery systems?
Rate-programmed drug delivery systems follow three designs: reservoir, matrix, and hybrid. Reservoir systems enclose the drug core within a rate-controlling membrane. Matrix systems embed the drug in a release-retarding material. Hybrid systems combine both approaches by embedding drug in a matrix and coating it with a polymer membrane, merging the consistent release of reservoir systems with the structural durability of matrix systems.
Q2: How do non-swelling reservoir systems control drug release?
Non-swelling reservoir systems use polymers like ethyl cellulose and polymethacrylates that do not hydrate in aqueous media. These polymers control drug release through membrane thickness, insolubility, slow dissolution, or porosity. This design is used in coated particles, pellets, or tablets to achieve predictable, sustained drug delivery without requiring membrane hydration.
Q3: What is the difference between hydrophilic and hydrophobic matrix systems?
Hydrophilic matrices use water-swellable polymers like HPMC that form porous structures and allow drug diffusion through the swollen matrix. Hydrophobic matrices use slowly soluble or insoluble materials like waxes or ethyl cellulose. Hydrophobic matrices can be porous, with drug mixed into polymer particles, or nonporous, with drug dispersed in molten polymer for controlled release.
Q4: How do swelling-controlled reservoir systems delay drug release?
Swelling-controlled reservoir systems use polymers such as HPMC that hydrate in aqueous media. Drug release begins only after the membrane absorbs water and hydrates, resulting in a delayed onset followed by steady release. This design allows precise timing of drug delivery initiation, making it useful for drugs requiring delayed therapeutic action.
Q5: What advantage do hybrid drug delivery systems offer over single-design systems?
Hybrid systems embed drug in a matrix and coat it with a polymer membrane, combining the consistent drug release of reservoir systems with the structural durability of matrix systems. This design provides superior control over drug delivery by leveraging the steady-state kinetics of reservoirs while maintaining the mechanical stability and longevity of matrix devices.
Q6: How does membrane thickness affect drug release in reservoir systems?
In non-swelling reservoir systems, membrane thickness is a critical parameter controlling drug release rate. Thicker membranes slow drug diffusion through the polymer, extending release duration, while thinner membranes accelerate release. By adjusting ethyl cellulose or polymethacrylate membrane thickness, manufacturers can precisely program drug release kinetics to match therapeutic requirements.
Q7: What role does porosity play in controlling drug release from matrix systems?
Porosity in matrix systems, particularly in hydrophobic matrices, creates pathways for drug diffusion and dissolution. Porous hydrophobic matrices mix drug and polymer particles, allowing fluid penetration and drug release through interconnected pores. Nonporous systems rely on drug solubility and polymer erosion, offering different release profiles suited to specific drug properties and therapeutic goals.